An observational study in Uterine Cervical Neoplasms and Cervical Cancer by FIGO Stage 2018, sponsored by Centre Hospitalier Universitaire de Nīmes. Recruiting at 1 site in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-07.
Sponsored by Centre Hospitalier Universitaire de Nīmes · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 147 studies in Uterine Cervical Neoplasms with a site in France — 31 open to participants now, 46 under way, 5 of them phase 3. Uterine Cervical Neoplasms · France.
Among the 147 studies in Uterine Cervical Neoplasms with a site in France, this one is the 19th largest by planned enrollment of the 30 observational ones that give a count, is one of 4 that started in 2026, is one of 30 observational ones, reaches primary completion later than 9 of the 45 other live ones, and was the 146th registered.
2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.
Browse Uterine Cervical Neoplasms studies →31 of the 147 studies in Uterine Cervical Neoplasms with a site in France are open now. Recruiting first, the newest first:
Centre Hospitalier Intercommunal Creteil · Sites in France
Ages 25–65
Merck Sharp & Dohme LLC · Sites in France, United States, Argentina and 26 more countries
Ages 18+ · Women only
Centre Paul Strauss · Sites in France
Ages 18+ · Women only
Institut Claudius Regaud · Sites in France
Ages 18+
International Agency for Research on Cancer · Sites in France
Ages 30–65 · Women only · Healthy volunteers
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
147 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 32 · Phase 2 36 · Phase 3 14 · Phase 4 1
First in 1996; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is below the median of 220 across 530 observational studies indexed under Uterine Cervical Neoplasms.
Median enrollment 210 across the 117 interventional studies, 174 across the 30 observational. Of the 92 that completed or were terminated, 15 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
43 of 147 have an industry lead sponsor. The 10 most frequent:
Centre Hospitalier Universitaire de Nīmes is the lead sponsor of 595 studies on the registry; 87 are open to participants now.
Centre Hospitalier Universitaire de Nīmes has 3 studies filed under Uterine Cervical Neoplasms — fewer than ten, so there is no comparison to draw.
12 of the studies in Uterine Cervical Neoplasms with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06392997ZIWIGEvaluation of Salivary RNA in Subjects Scheduled for Surgery for a Gynecologic Pathology | 2026-12 |
| NCT06533059Alterome Therapeutics, Inc.A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors | 2026-12-29 |
| NCT05527184AbbVieFirst in Human Study of IMGN151 in Recurrent Gynaecological Cancers | 2027-02 |
| NCT06238479Eli Lilly and CompanyA Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors | 2027-03 |
| NCT06923761Grey Wolf TherapeuticsEMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1) | 2027-04-30 |
Add all 12 to your calendar (.ics) → With an account.
Among the 147 studies in Uterine Cervical Neoplasms with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Cervical cancer is the fourth most common cancer in women worldwide, with approximately 604,000 new cases in 2020.Treatment for locally advanced cervical cancer is based on a combination of radiotherapy and chemotherapy. The response to concomitant chemoradiotherapy vary from one woman to another. Predicting the response to these treatments would allow early consideration of alternative therapies for patients identified as less responsive to standard treatments. A 5-year recurrence-free survival is approximately 79% for stages IB and IIA and 59% for stages III and IVA, with approximately 36% of local failures despite chemoradiotherapy. In a few studies,the radiomic MRI approach in locally advanced cervical cancers has shown to be prognostic for locoregional recurrence or survival but these models still need to be explored and validated.The EPICOL cohort, a clinical-biological cohort of 136 patients treated with chemoradiotherapy for locally advanced cervical cancer at the Montpellier Cancer Institute or Nîmes University Hospital, will be used to develop a predictive model of response to chemoradiotherapy based on radiomic data from pelvic MRIs before and after treatment.
Cervical cancer is an invasive cancer that develops from the squamous epithelium of the cervix. Worldwide, cervical cancer is the fourth most common cancer in women, with approximately 604,000 new cases in 2020.Treatment for locally advanced cervical cancer (FIGO stage IB3 to IVA) is based on a combination of radiotherapy and chemotherapy (cisplatin 40 mg/m2 x5 or 6 or carboplatin area under the curve 2 if cisplatin is contraindicated). Responses to concomitant chemoradiotherapy remain highly heterogeneous from one woman to another, and predicting the response to these treatments would allow early consideration of alternative therapies for patients identified as less responsive to standard treatments. Indeed, 5-year recurrence-free survival is approximately 79% for stages IB and IIA and 59% for stages III and IVA, with approximately 36% of local failures despite chemoradiotherapy.
The radiomic MRI approach in locally advanced cervical cancers has shown in a few studies to be prognostic for locoregional recurrence or survival. However, these models still need to be explored and validated before they can be implemented in routine clinical practice.
The EPICOL cohort is a clinical-biological cohort of 136 patients treated with chemoradiotherapy for locally advanced cervical cancer at the Montpellier Cancer Institute or Nîmes University Hospital.
The aim is to develop a predictive model of response to chemoradiotherapy based on radiomic data from pelvic MRIs before and after treatment from the EPICOL cohort.
For this study, data from 120 patients for whom we have MRI data from the EPICOL cohort (136 patients included) will be used.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Prognostic role of a magnetic resonance imaging radiomic model on progression-free survival in patients treated for locally advanced cervical cancer.
Time from diagnosis to death from any cause or progression (according to RECIST v1.1 criteria) at 24 months of follow-up.
Time frame: Month 24
Prognostic role of an magnetic resonance imaging radiomic model on overall survival in patients treated for locally advanced cervical cancer.
Time between treatment initiation and death from any cause at 24 months of follow-up.
Time frame: Month 24
Correlation between the radiomic magnetic imaging radiomic model and Programmed cell Death protein 1 (PD-L1) expression.
Collection of Programmed cell Death protein 1 (PD-L1) expression levels from biopsies from the EPICOL cohort.
Time frame: Month 24
Correlation between the radiomic magnetic resonance imaging model and tumor-infiltrating lymphocytes (TILs).
Collection of tumor-infiltrating lymphocyte (TIL) expression levels in biopsies from the EPICOL cohort.
Time frame: Month 24
Plan to share: Undecided
Start is estimated for Jan 2026; primary completion for Aug 2026, 7 months later.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Universitaire de Nīmes →